Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

AI can help design AI systems: automating architecture choices, discovering algorithms, and optimizing hardware ...

On the buying side, ARK made a notable purchase of 17,386 shares of Coinbase Global Inc (PRE-REINCORPORATION) (NASDAQ:COIN) across its ARKK, ARKW, and ARKF ETFs, with a total dollar value of ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Toward the end of this decade, a choice may face the species that could reshape its interactions with intelligence itself and this choice is whether or not it shall allow highly advanced AI systems to ...